Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-24
    E.g., 2018-02-24

Articles

Pages

79583 items
12:38 PM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Google's deep-learning algorithm predicts CV risk

Google Inc. (Mountain View, Calif.) and colleagues reported that a deep-learning algorithm was able to use anatomical features such as the optic disc and blood vessels from retinal fundus photographs to predict cardiovascular risk factors....
12:36 PM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

FDA clears MabSpace's PD-L1 mAb for first-in-human trial

MabSpace Biosciences Co. Ltd. (Suzhou, China) said FDA approved an IND to begin a first-in-human trial of MSB2311 to treat advanced or metastatic solid tumors. MSB2311, a humanized IgG1 mAb targeting PD-L1, will be MabSpace's...
12:35 PM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Eli Lilly stops Phase II trial of BTK inhibitor in RA

Eli Lilly and Co. (NYSE:LLY) discontinued the Phase II RAjuvenate trial of HM71224 (LY3337641) to treat rheumatoid arthritis after a planned analysis showed that the difference between the active and placebo control arms "was not...
12:35 PM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Wilson Therapeutics starts Phase III of WTX101 for Wilson's disease

The single-blind, international trial will enroll about 100 patients. The primary endpoint is non-inferiority of WTX101 to standard of care on copper control as measured by the percentage change in free copper levels in blood...
12:35 PM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Roche reports Phase II data for bispecific DME candidate

Roche (SIX:ROG; OTCQX:RHHBY) reported data from the Phase II BOULEVARD trial to treat diabetic macular edema (DME) showing that once-monthly 6 mg intravitreal RG7716 for 20 weeks met the primary endpoint of improving mean best...
12:35 PM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Apellis reports 18-month Phase II data for GA candidate

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) reported 18-month data from the Phase II FILLY trial to treat geographic atrophy showing that APL-2 for 12 months maintained significant reductions in lesion growth at six months after stopping treatment....
12:34 PM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

AbbVie's elagolix meets in Phase III for uterine fibroids

AbbVie Inc. (NYSE:ABBV) said elagolix (ABT-620) met the primary and all ranked secondary endpoints in the Phase III ELARIS UF-I (M12-815) trial to treat uterine fibroids. The trial is the first of two replicate Phase...
12:34 PM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Akari's Coversin meets in Phase II for PNH

Akari Therapeutics plc (NASDAQ:AKTX) said subcutaneous Coversin met the primary endpoint of reducing lactic dehydrogenase (LDH) to ≤1.8 times the upper limit of normal (ULN) at day 28 in the open-label Phase II COBALT trial...
12:33 PM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Celgene reports Phase II data for Otezla in UC

Celgene Corp. (NASAQ:CELG) reported data from a Phase II trial in 170 patients with active ulcerative colitis (UC) showing that twice-daily 30 and 40 mg doses of oral Otezla apremilast (CC-10004) led to clinical remission...
12:33 PM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Exelixis' cabozantinib meets in Phase II for first-line thyroid cancer

Exelixis Inc. (NASDAQ:EXEL) said once-daily 60 mg oral cabozantinib as first-line treatment met the primary endpoint of objective response rate (ORR) in a Phase II trial to treat metastatic radioiodine-refractory differentiated thyroid cancer. The pre-specified...

Pages